[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0949928A4 - Androgenic and bisphosphonic agents coadministered to treat diseases - Google Patents

Androgenic and bisphosphonic agents coadministered to treat diseases

Info

Publication number
EP0949928A4
EP0949928A4 EP97949529A EP97949529A EP0949928A4 EP 0949928 A4 EP0949928 A4 EP 0949928A4 EP 97949529 A EP97949529 A EP 97949529A EP 97949529 A EP97949529 A EP 97949529A EP 0949928 A4 EP0949928 A4 EP 0949928A4
Authority
EP
European Patent Office
Prior art keywords
bisphosphonic
androgenic
treat diseases
coadministered
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97949529A
Other languages
German (de)
French (fr)
Other versions
EP0949928A1 (en
Inventor
Azriel Schmidt
Gideon Rodan
Shun-Ichi Harada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700697.7A external-priority patent/GB9700697D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0949928A1 publication Critical patent/EP0949928A1/en
Publication of EP0949928A4 publication Critical patent/EP0949928A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97949529A 1996-11-25 1997-11-21 Androgenic and bisphosphonic agents coadministered to treat diseases Withdrawn EP0949928A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3173496P 1996-11-25 1996-11-25
US31734P 1996-11-25
US3234196P 1996-12-04 1996-12-04
US32341P 1996-12-04
GB9700697 1997-01-15
GBGB9700697.7A GB9700697D0 (en) 1997-01-15 1997-01-15 Combination of an androgen and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
PCT/US1997/021306 WO1998023274A1 (en) 1996-11-25 1997-11-21 Androgenic and bisphosphonic agents coadministered to treat diseases

Publications (2)

Publication Number Publication Date
EP0949928A1 EP0949928A1 (en) 1999-10-20
EP0949928A4 true EP0949928A4 (en) 2000-09-13

Family

ID=27268672

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97949529A Withdrawn EP0949928A4 (en) 1996-11-25 1997-11-21 Androgenic and bisphosphonic agents coadministered to treat diseases

Country Status (5)

Country Link
EP (1) EP0949928A4 (en)
JP (1) JP2001507338A (en)
AU (1) AU743121B2 (en)
CA (1) CA2271664A1 (en)
WO (1) WO1998023274A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013994A1 (en) * 1998-10-30 2001-01-31 Gador Sa PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES.
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6605591B1 (en) 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
EP1640010A1 (en) * 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent inducing increase in bone mass
JO3394B1 (en) * 2014-07-04 2019-10-20 Osteo Pharma B V Compositions and products for use in the treatment of bone fractures and defects

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014474A1 (en) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Methods for the treatment of osteoporosis
EP0555845A2 (en) * 1992-02-14 1993-08-18 Mitsubishi Kasei Corporation Steroid derivatives
WO1993024128A1 (en) * 1992-06-03 1993-12-09 Mattern Et Partner Pharmazeutische Entwicklungs- Und Handelsges. Mbh Androgens for stimulating the central nervous system and for treating osteoporosis
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5547685A (en) * 1995-05-16 1996-08-20 Eli Lilly And Company Methods for inhibiting bone loss with vanadyl sulfate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014474A1 (en) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Methods for the treatment of osteoporosis
EP0555845A2 (en) * 1992-02-14 1993-08-18 Mitsubishi Kasei Corporation Steroid derivatives
WO1993024128A1 (en) * 1992-06-03 1993-12-09 Mattern Et Partner Pharmazeutische Entwicklungs- Und Handelsges. Mbh Androgens for stimulating the central nervous system and for treating osteoporosis
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHESTNUT, CHARLES H., III (1) ET AL: "Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling.", AMERICAN JOURNAL OF MEDICINE, (1995) VOL. 99, NO. 2, PP. 144-152., XP000916282 *
GLUECK, CHARLES J. (1) ET AL: "Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with stanozolol.", AMERICAN JOURNAL OF HEMATOLOGY, (1995) VOL. 48, NO. 4, PP. 213-220., XP000916283 *
REID, IAN R. (1) ET AL: "Glucocorticoid osteoporosis.", JOURNAL OF ASTHMA, (1994) VOL. 31, NO. 1, PP. 7-18., XP000916273 *
See also references of WO9823274A1 *
WANG, C. (1) ET AL: "Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men: A clinical research center study.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, (1996) VOL. 81, NO. 10, PP. 3654-3662., XP000916279 *

Also Published As

Publication number Publication date
JP2001507338A (en) 2001-06-05
WO1998023274A1 (en) 1998-06-04
AU743121B2 (en) 2002-01-17
AU7408698A (en) 1998-06-22
CA2271664A1 (en) 1998-06-04
EP0949928A1 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
GB2331015B (en) Therapeutic methods and compositions involving isoflavones
GR3036364T3 (en) Compositions and methods for treating or preventing inflammatory diseases
HUP0004170A3 (en) Methods and materials for treating and preventing inflammation ofmucosal tissue
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
IL132758A0 (en) Methods for treating inflammation and inflammatory diseases using padprt
AU5439996A (en) Compositions and methods for treating pain
PL331465A1 (en) Novel compounds and agents for treating diseases associated with triptase activity
EP0938901A4 (en) Medicinal compositions for treating liver diseases
GB9600235D0 (en) Therapeutic agents
GB9603755D0 (en) Therapeutic agents
PL317579A1 (en) Benzopyranes and their application as therapeutic agents
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
IL111554A (en) Methods and compositions for hair treatment
EP0949928A4 (en) Androgenic and bisphosphonic agents coadministered to treat diseases
EP0921803A4 (en) Methods for preventing and treating pestivirus infection and associated diseases
SG65766A1 (en) Composition for preventing and treating gingival diseases
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
AU5425098A (en) Compounds and methods to treat infectious diseases
IL120265A0 (en) Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
IL126623A0 (en) Pharmaceutical compositions and kits for dhea combined therapy
IL134282A0 (en) Inhibition of unwanted hormone action in plants
IL114723A0 (en) Tetraacylic triterpenes and their preparation
AU6592496A (en) Compositions and methods for treating specific gene expression-related diseases and disorders in humans
GB9604036D0 (en) Therapeutic agents
GB9603136D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000727

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020307

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030513